Inicio・Lista de Acciones・Roivant Sciences Ltd

Roivant Sciences Ltd

Cerrado

SectorSanidad

41 0.44

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

40.7

Máximo

41.18

Métricas clave
By Trading Economics
Ingresos	-646M -291M
Ventas	-1.1M 1.4M
BPA	-0.45
Margen de beneficios	-20,152.982
Empleados	721
EBITDA	-743M -288M

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	1.2B 25B
Apertura anterior	40.56
Cierre anterior	41

Noticias sobre sentimiento de mercado

By Acuity

50%

124 / 339 Clasificación en Healthcare

Roivant Sciences Ltd Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

11 sept 2026, 20:13 UTC

Roivant Sciences Ltd. shares are lower in after-market trading, amid broader market concerns over potential Federal Reserve interest rate hikes following recent inflation data.

10 sept 2026, 23:31 UTC

Roivant Sciences Ltd shares are lower in after-market trading, with no specific news identified to explain the decline. The stock remains above its 20-day moving average.

9 sept 2026, 23:06 UTC

Roivant Sciences Ltd shares are higher in after-market hours, maintaining a narrow trading range since Wednesday's close and staying above the 20-day moving average.

8 sept 2026, 23:06 UTC

Event

News

Roivant Sciences Ltd shares are lower in after-market hours despite positive Phase 2 trial results for mosliciguat targeting pulmonary hypertension.

4 sept 2026, 22:51 UTC

Correlated Moves

Roivant Sciences Ltd shares are lower in after-market trading, reflecting broader market declines and negative sentiment in the biotech sector.

2 sept 2026, 20:08 UTC

Roivant Sciences Ltd shares are lower today, breaking a trend of higher closes. No specific news was identified to explain the decline.

1 sept 2026, 19:36 UTC

Roivant Sciences Ltd is trading lower amid broader market sentiment and rising oil prices. The stock remains below its 20-day moving average.

31 ago 2026, 22:01 UTC

Roivant Sciences Ltd shares are higher in after-hours trading, showing modest gains since Monday's close amid rising oil prices and geopolitical tensions.

29 ago 2026, 00:01 UTC

Roivant Sciences Ltd shares are higher in after-market hours, reflecting notable activity despite a retracement from earlier gains. No specific news was identified.

28 ago 2026, 23:01 UTC

Roivant Sciences Ltd shares are higher in after-market trading, reflecting notable activity following Friday's close, despite no specific news identified.

27 ago 2026, 23:02 UTC

Roivant Sciences Ltd. shares are higher in after-market trading, remaining above the 20-day moving average despite earlier fluctuations during the session.

26 ago 2026, 22:41 UTC

Roivant Sciences Ltd is trading higher in after-market hours, reflecting broader market gains. The asset has closed higher for three consecutive sessions.

25 ago 2026, 23:16 UTC

Roivant Sciences Ltd. shares are lower in after-market trading, continuing a steady decline since Tuesday's close, though still above the 20-day moving average.

24 ago 2026, 23:01 UTC

Roivant Sciences Ltd. shares are lower in after-market trading, retracing from an earlier session high while remaining above the 20-day moving average.

21 ago 2026, 19:31 UTC

Roivant Sciences is declining in Friday's session, with no specific news identified. The stock has seen unusually high trading volume today.

20 ago 2026, 23:21 UTC

Roivant Sciences Ltd. shares are lower in after-market trading amid broader market pressures, including rising bond yields and concerns over high borrowing costs.

19 ago 2026, 23:26 UTC

Roivant Sciences Ltd is seeing upward momentum in after-market trading, recovering from a prior dip and nearing the upper end of its one-month trading range.

18 ago 2026, 23:01 UTC

Roivant Sciences Ltd shares are lower in after-market trading, declining notably after Tuesday's close amid rising U.S. Treasury yields and inflation concerns.

17 ago 2026, 19:36 UTC

Roivant Sciences shares are roughly flat amid broader market declines. The bond market faces upward pressure on yields due to inflation concerns.

14 ago 2026, 19:26 UTC

Roivant Sciences Ltd. remains near unchanged amid no specific news, fluctuating around flat levels during Friday's session. It is 4.29% above its 20-day moving average.

13 ago 2026, 19:36 UTC

Roivant Sciences Ltd is trading modestly higher amid broader market dynamics. Initial jobless claims rose above expectations, indicating potential softness in the labor market.

12 ago 2026, 22:11 UTC

Roivant Sciences shares are higher in after-market trading, driven by a positive market reaction to the July Consumer Price Index report.

11 ago 2026, 21:01 UTC

Roivant Sciences Ltd shares are lower in after-market hours, continuing recent declines amid broader market volatility linked to U.S.-Iran relations.

10 ago 2026, 23:02 UTC

Roivant Sciences Ltd shares are higher in after-market hours, trading above their 20-day moving average and near the upper end of their one-month range.

7 ago 2026, 20:02 UTC

Event

News

Roivant Sciences Ltd shares are higher as HC Wainwright maintains a Buy rating and raises the price target to $41 amid positive developments in its product pipeline.

6 ago 2026, 20:03 UTC

News

Event

Roivant Sciences reported a net loss of $290.6 million in Q1, exceeding expectations. Shares are higher despite pulling back from session highs earlier.

5 ago 2026, 22:01 UTC

Roivant Sciences Ltd shares are higher in after-market trading, reflecting notable activity following Wednesday's close. The stock is positioned above its 20-day moving average.

4 ago 2026, 20:02 UTC

Roivant Sciences is rising amid positive market sentiment and declining crude oil prices. Remarks from Treasury Secretary Scott Bessent also support the favorable environment.

3 ago 2026, 20:06 UTC

Roivant Sciences Ltd shares are declining today, breaking a trend of higher closes. Broader market indices are up, but no specific news explains the drop.

31 jul 2026, 20:02 UTC

Roivant Sciences Ltd shares are lower today amid significant declines in biotechnology stocks, breaking a trend of higher daily closes since Thursday.

Comparación entre iguales

Cambio de precio

Roivant Sciences Ltd previsión

Consenso

By TipRanks

Compra Fuerte

8 ratings

Comprar

Mantener

Vender

De acuerdo con 8 analistas que ofrecen calificaciones bursátiles a para Roivant Sciences Ltd Dist en los últimos 3 meses.

Sentimiento

By Acuity

124 / 339 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Roivant Sciences Ltd

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom.